Influenza A Virus IgA Control Serum BC1231A

$94.00

Summary

Virion/Serion Diagnostic Kit Control for research use (RUO)
Influenza A Virus IgA Control Serum
Applications: ELISA
IgA control serum
Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
3 mL

SKU: BC1231A Categories: control serum, Virion/Serion kits Tags: ELISA control serum, IgA, Influenza Virus

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Influenza A Virus reactive IgA
species reactivity	Influenza A Virus
applications	ELISA
assay type	Indirect & quantitative
available size	3 mL

Influenza A Virus IgA Control Serum BC1231A

kit
Research area Infectious Disease
Storage Store at 2-8°C.
Associated products Influenza A Virus IgA Control Serum (BC1231A) Influenza A Virus IgG Control Serum (BC1231G) Influenza A Virus IgM Control Serum (BC1231M) Influenza A Virus IgA ELISA Kit (ESR1231A) Influenza A Virus IgG ELISA Kit (ESR1231G) Influenza A Virus IgM ELISA Kit (ESR1231M)

target relevance

human antibody anti-Influenza Virus

Influenza Virus

Description
Virus that causes influenza (flu)

Structure
Influenza viruses are enveloped, negative-sense, single-stranded RNA viruses belonging to the Orthomyxoviridae family. The viral genome is segmented into multiple RNA molecules, allowing genetic reassortment between different strains. Influenza A and B viruses are the primary causes of seasonal influenza in humans, while Influenza A viruses also infect a wide range of animal species including birds, pigs, horses, and marine mammals. The viral envelope contains the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA), which are responsible for viral attachment, entry, and release from host cells. Influenza viruses are characterized by a high mutation rate, resulting in antigenic drift and the emergence of new variants. Periodically, reassortment events between different influenza strains can result in antigenic shift, leading to the emergence of pandemic viruses.

Diagnosis
The diagnosis of influenza is performed by the detection of viral RNA, viral antigens, or influenza-specific antibodies. Molecular methods such as reverse transcription polymerase chain reaction (RT-PCR) are considered the gold standard for the detection and differentiation of influenza virus types and subtypes. Rapid influenza diagnostic tests (RIDTs) detect viral antigens and provide results within minutes but generally have lower sensitivity than molecular methods. Serological assays including ELISA and hemagglutination inhibition tests may be used to determine previous exposure, monitor immune responses, or support epidemiological investigations. Influenza-specific IgM antibodies typically appear during the acute phase of infection, while IgG antibodies develop later and may persist for years, providing varying degrees of immunity against related viral strains.

Symptoms
Influenza viruses are highly contagious respiratory pathogens that spread primarily through respiratory droplets and aerosols generated by infected individuals. Following an incubation period of approximately one to four days, influenza typically presents with abrupt onset of fever, chills, headache, myalgia, fatigue, sore throat, and dry cough. Additional symptoms may include nasal congestion, runny nose, and loss of appetite. Although most infections are self-limiting, severe disease can occur in young children, elderly individuals, pregnant women, and immunocompromised patients. Complications include viral pneumonia, secondary bacterial pneumonia, myocarditis, encephalitis, and acute respiratory distress syndrome (ARDS). Seasonal influenza is responsible for substantial morbidity and mortality worldwide, and periodic pandemics caused by novel influenza A strains can result in widespread outbreaks with significant public health impact.

Data

FAQ & Publications

Frequently Asked Questions

What is the intended use of the Influenza A Virus IgA Control Serum BC1231A?

The Influenza A Virus IgA Control Serum BC1231A is used as a control serum for ELISA applications, specifically designed for indirect and quantitative assays targeting Influenza A Virus reactive IgA antibodies.

How should the Influenza A Virus IgA Control Serum BC1231A be stored to maintain stability?

This control serum should be stored at 2-8°C to preserve its stability and ensure reliable performance in ELISA assays.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
BC1231A protocol

Documents

#
Please enter your product and batch number here.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Influenza A Virus IgA Control Serum BC1231A

Data

FAQ & Publications

Protocols

Documents

Related Technical Resources & Posts

Reviews

Related Products

Candida albicans IgA Control Serum BC117A

Influenza B Virus IgA Control Serum BC1232A

Campylobacter jejuni IgA Control Serum BC139A

Influenza B Virus IgG Control Serum BC1232G

Brucella IgA Control Serum BC116A

Influenza B Virus IgM Control Serum BC1232M

Bordetella pertussis IgA Control Serum BC120A

Influenza A Virus IgG Control Serum BC1231G

Adenovirus IgA Control Serum BC128A

Helicobacter pylori IgA Control Serum BC118A

Enterovirus IgA Control Serum BC133A

Echovirus IgA Control Serum BC135A

Coxsackie IgA Virus Control Serum BC134A

Chlamydia trachomatis IgA Control Serum BC1372A

Chlamydia pneumoniae IgA Control Serum BC1371A